Citations

Showing 10 of 108152 citations.

Emerging role of extracellular vesicles in liver diseases
Malhi, Harmeet , Malhi, Harmeet

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | September 23, 2019 | Volume: 317 | Issue: 5 | Pages: G739-G749

10.1152/ajpgi.00183.2019 | PMID 31545919 Get It

Extracellular vesicles (EVs) are membrane-defined nanoparticles released by most cell types. The EVs released by cells may differ quantitatively and qualitatively from physiological states to disease states. There are several unique properties of EVs, including their proteins, lipids and nucleic acid cargoes, stability in circulation, and presence in biofluids, which make them a critical vector for cell-to-cell communication and impart utility as a biomarker. EVs may also serve as a vehicle for selective cargo secretion. Similarly, EV cargo may be selectively manipulated for targeted therapeutic delivery. In this review an overview is provided on the EV classification, biogenesis, and secretion pathways, which are conserved across cell types. Next, cargo characterization and effector cell responses are discussed in the context of nonalcoholic steatohepatitis, alcoholic hepatitis, and acetaminophen-induced liver injury. The review also discusses the potential biomarker and therapeutic uses of circulating EVs.
Structural and functional analyses reveal promiscuous and species specific use of ephrin receptors by Cedar virus
Laing, Eric D. , Navaratnarajah, Chanakha K. , Silva, Sofia Cheliout Da, Petzing, Stephanie R., Xu, Yan , Sterling, Spencer L. , Wang, Lin‐Fa , Amaya, Moushimi , Nikolov, Dimitar B. , Cattaneo, Roberto , Broder, Christopher C. , Xu, Kai , Wang, Lin-Fa , Cattaneo, Roberto , Broder, Christopher C , Xu, Kai , Xu, Yan, Marsh, Glenn A.

Mayo Clinic

Proceedings of the National Academy of Sciences | September 23, 2019 | Volume: 116 | Issue: 41 | Pages: 20707-20715

10.1073/pnas.1911773116 | PMID 31548390 Get It

Cedar virus (CedV) is a bat-borne henipavirus related to Nipah virus (NiV) and Hendra virus (HeV), zoonotic agents of fatal human disease. CedV receptor-binding protein (G) shares only ∼30% sequence identity with those of NiV and HeV, although they can all use ephrin-B2 as an entry receptor. We demonstrate that CedV also enters cells through additional B- and A-class ephrins (ephrin-B1, ephrin-A2, and ephrin-A5) and report the crystal structure of the CedV G ectodomain alone and in complex with ephrin-B1 or ephrin-B2. The CedV G receptor-binding site is structurally distinct from other henipaviruses, underlying its capability to accommodate additional ephrin receptors. We also show that CedV can enter cells through mouse ephrin-A1 but not human ephrin-A1, which differ by 1 residue in the key contact region. This is evidence of species specific ephrin receptor usage by a henipavirus, and implicates additional ephrin receptors in potential zoonotic transmission.
American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies
Tuan, Rocky S. , Awad, Hani A. , Bunnell, Bruce A. , Colnot, Céline , Drissi, Hicham , Dyment, Nathaniel A. , Fortier, Lisa A. , Guldberg, Robert E. , Little, David G. , Marshall, Mary Faith , Mao, Jeremy J. , Proffen, Benedikt L. , Rosen, Vicki , Thomopoulos, Stavros , Serra, Rosa , Tuan, Rocky S , Awad, Hani A , Drake, Matthew T. , Kandel, Rita A. , Proffen, Benedikt L , Rodeo, Scott A , Schwarz, Edward M , Serra, Rosa , Dyment, Nathaniel A , O’Keefe, Regis J. , Lane, Nancy E. , Barry, Frank , Nakamura, Norimasa , Rodeo, Scott A. , Schwarz, Edward M.

Mayo Clinic

Journal of Bone and Mineral Research | September 23, 2019 | Volume: 35 | Issue: 1 | Pages: 3-17

10.1002/jbmr.3839 | PMID 31545883 Get It

ABSTRACT Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2019 American Society for Bone and Mineral Research.
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
Yuan, Chen , Sato, Kaori , Hollis, Bruce W. , Zhang, Sui , Niedzwiecki, Donna , Ou, Fang‐Shu , Chang, I-Wen, O’Neil, Bert H. , Innocenti, Federico , Lenz, Heinz‐Josef , Blanke, Charles D. , Goldberg, Richard M. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Ng, Kimmie , Venook, Alan P , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Venook, Alan P. , Mayer, Robert J. , Yuan, Chen

Mayo Clinic

Clinical Cancer Research | September 23, 2019 | Volume: 25 | Issue: 24 | Pages: 7497-7505

10.1158/1078-0432.ccr-19-0877 | PMID 31548349 Get It

Abstract Purpose: Previous studies have suggested that higher circulating 25-hydroxyvitamin D [25(OH)D] levels are associated with decreased colorectal cancer risk and improved survival. However, the influence of vitamin D status on disease progression and patient survival remains largely unknown for patients with advanced or metastatic colorectal cancer. Experimental Design: We prospectively collected blood samples in 1,041 patients with previously untreated advanced or metastatic colorectal cancer participating in a randomized phase III clinical trial of first-line chemotherapy plus biologic therapy. We examined the association of baseline plasma 25(OH)D levels with overall survival (OS) and progression-free survival (PFS). Cox proportional hazards models were used to calculate hazard ratios (HRs) and confidence intervals (CIs), adjusted for prognostic factors and confounders. Results: At study entry, 63% of patients were vitamin D deficient (<20 ng/mL) and 31% were vitamin D insufficient (20–<30 ng/mL). Higher 25(OH)D levels were associated with an improvement in OS and PFS (Ptrend = 0.0009 and 0.03, respectively). Compared with patients in the bottom quintile of 25(OH)D (≤10.8 ng/mL), those in the top quintile (≥24.1 ng/mL) had a multivariable-adjusted HR of 0.66 (95% CI, 0.53–0.83) for OS and 0.81 (95% CI, 0.66–1.00) for PFS. The improved survival associated with higher 25(OH)D levels was consistent across patient subgroups of prognostic patient and tumor characteristics. Conclusions: In this large cohort of patients with advanced or metastatic colorectal cancer, higher plasma 25(OH)D levels were associated with improved OS and PFS. Clinical trials assessing the benefit of vitamin D supplementation in patients with colorectal cancer are warranted.
Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation
Dadlani, Vikash, Kaur, Ravinder Jeet , Stegall, Mark D. , Xyda, S, Bonner, Keisha , Smith, Byron H. , Thapa, Prabin , Dean, Patrick G. , Kudva, Yogish C. , Stegall, Mark, Xyda, Souzana-Eirini, Kumari, Kanchan, Smith, Byron , Kudva, Yogish C. , Stegall, Mark D , Kumari, Kanchan

Mayo Clinic

Clinical Transplantation | September 23, 2019 | Volume: 33 | Issue: 10 | Pages: No page available

10.1111/ctr.13719 | PMID 31545535 Get It

AbstractBackgroundCurrent therapy for Type 1 diabetes (T1D) is characterized by significant glucose variability (GV). Pancreas transplantation (PT) is performed in certain T1D patients with and without end‐stage renal disease. To date, GV has been examined to a limited extent after PT.MethodsWe investigated GV using continuous glucose monitoring (CGM) 3‐6 weeks after PT.ResultsEleven patients had simultaneous kidney pancreas transplantation (SPK), nine pancreas after kidney (PAK), and six pancreas transplantation alone (PTA). Mean CGM showed no difference between SPK, 126.5 ± 13.9, PAK 119.9 ± 12.8, and PTA 131.1 ± 29 mg/dL (P value .6). Percentage of time in range (TIR, 70‐180 mg/dL) was 92% for SPK, 93.4% in PAK, and 88.5% in PTA with only 0.3%, 1.5%, and 0.3% of time <70 mg/dL. Percentage >180 mg/dL was 7.9% for SPK, 4.9% PAK, and 11% in PTA. Other measures of GV were similar in the three cohorts. In six patients, CGM was performed before and after PT and improved significantly. GV was also better compared with a matched cohort of T1D patients.ConclusionsAll 3 types of PT resulted in excellent glucose control 3‐6 weeks post‐procedure. CGM outcomes represent an important objective outcome after PT.
Women in Pediatrics: Progress, Barriers, and Opportunities for Equity, Diversity, and Inclusion
Asante, Philomena A., Marcelin, Jasmine R , Poorman, Julie A., Salles, Arghavan , Oxentenko, Amy S. , Marcelin, Jasmine , Spector, Nancy Dollase , Larson, Allison R , Silver, Julie K.

Mayo Clinic

Pediatrics | September 23, 2019 | Volume: 144 | Issue: 5 | Pages: No page available

10.1542/peds.2019-2149 | PMID 31548337 Get It

Gender bias and discrimination have profound and far-reaching effects on the health care workforce, delivery of patient care, and advancement of science and are antithetical to the principles of professionalism. In the quest for gender equity, medicine, with its abundance of highly educated and qualified women, should be leading the way. The sheer number of women who comprise the majority of pediatricians in the United States suggests this specialty has a unique opportunity to stand out as progressively equitable. Indeed, there has been much progress to celebrate for women in medicine and pediatrics. However, many challenges remain, and there are areas in which progress is too slow, stalled, or even regressing. The fair treatment of women pediatricians will require enhanced and simultaneous commitment from leaders in 4 key gatekeeper groups: academic medical centers, hospitals, health care organizations, and practices; medical societies; journals; and funding agencies. In this report, we describe the 6-step equity, diversity, and inclusion cycle, which provides a strategic methodology to (1) examine equity, diversity, and inclusion data; (2) share results with stakeholders; (3) investigate causality; (4) implement strategic interventions; (5) track outcomes and adjust strategies; and (6) disseminate results. Next steps include the enforcement of a climate of transparency and accountability, with leaders prioritizing and financially supporting workforce gender equity. This scientific and data-driven approach will accelerate progress and help pave a pathway to better health care and science.
PharmVar GeneFocus: CYP2D6
Nofziger, Charity , Turner, Amy , Whirl‐Carrillo, Michelle , Agúndez, José A. G. , Black, John L. , Dunnenberger, Henry M. , Ruaño, Gualberto , Kennedy, Martin A. , Hachad, Houda , Klein, Teri E. , Turner, Amy J , Whirl-Carrillo, Michelle , Agúndez, José A G , Black, John L , Dunnenberger, Henry M , Kennedy, Martin A , Hachad, Houda , Gaedigk, Andrea , Klein, Teri E , Sangkuhl, Katrin , Phillips, Michael , Gaedigk, Andrea

Mayo Clinic

Clinical Pharmacology & Therapeutics | September 23, 2019 | Volume: 107 | Issue: 1 | Pages: 154-170

10.1002/cpt.1643 | PMID 31544239 Get It

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism of numerous drugs and, thus, can impact drug efficacy and safety. This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Safety of salpingectomy at time of delivery
Parikh, Pavan , Kim, Sharon , Hathcock, Matthew , Torbenson, Vanessa E. , Raju, Rubin

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | September 23, 2019 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1080/14767058.2019.1671328 | PMID 31544559 Get It